

31 October 2024

PureTech Health plc

PDMR Notification

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces the transfer of shares by a non-executive director ("PDMR").

The Company's total issued ordinary share capital is 257,927,489 shares, 18,506,177 shares of which are held in treasury by the Company.

PDMR Notification

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated			
a)	Name	John LaMattina, PhD		
2	Reason for the notification			
a)	Position/status	Non-Executive Director		
b)	Initial notification/Amendment	Initial Notification		
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	PureTech Health plc		
b)	LEI	213800LVPDNO2Z9T9I39		
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument	Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74		
b)	Nature of the transaction	The transferred shares were held in a charitable trust over which Dr. LaMattina has control. Dr. LaMattina periodically transfers shares from this trust to his alma mater, Boston College, as a form of support.		
c)	Price(s) and volume(s)	Individual	Price	Volume
		John LaMattina	Nil	52,640
e)	Date of the transaction	29 October 2024		
f)	Place of the transaction	Outside of a trading venue		

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit [www.puretechhealth.com](http://www.puretechhealth.com) or connect with us on X (formerly Twitter) @puretechh.

Contact:

PureTech

Investor Relations  
IR@puretechhealth.com

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEFLFXZBLEFBQ